Ahmed Elmahy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ahmed Elmahy has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Toby Prevost
King's College London London UK
2 shared publications - Ann Hutchinson
Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, Hull, UK
2 shared publications - Anthony Paulo Sunjaya
School of Population Health and The George Institute for Global Health, UNSW Sydney, Sydney, Australia
2 shared publications - David Alexander Scott
Southampton Health Technology Assessments Centre, University of Southampton, UK
2 shared publications - Elena Smets
ArtiQ, Leuven, Belgium
2 shared publications - Erika Kennington
Asthma+Lung UK, The White Chapel Building, London
2 shared publications
Latest Publications
- Open Access
Redesigning Isolation Practices: Evaluation of a Comprehensive Protocol for Respiratory Virus Control Including Cycle Threshold (Ct) Value Dynamics
The recent literature has debunked the widespread hypothesis that viruses are primarily transmitted via droplets and not beyond 1.5 m, and transmission via contact has been downplayed. Hence, an evidence-based revision of the existing isolation guidelines for respiratory viruses was needed. Therefore, a completely new protocol for respiratory virus isolation in terms of personal protective equipment and patient room air purification was evaluated. Isolation relief criteria based on Ct values in follow-up sampling were assessed. A Ct value of <28 was employed as a proxy for potential active replication and associated transmissibility. Between 25% and 50% of patients who tested positive for RSV, HRV, hMPV, or SARS-CoV-2 continued to exhibit high viral loads on day 7 post-initial diagnosis, underscoring the potential for sustained infectivity. Hence, the discontinuation of isolation measures for these patients without follow-up testing may carry a considerable risk of ongoing viral transmission. On the contrary, only 7% of patients positive for Flu and 14% for PIV had a follow-up sample on day 7 with a Ct value of less than 28. Ct values increased more rapidly in influenza, indicating faster viral clearance compared to other respiratory viruses. Based on these results, the policy of a standard 7-day isolation period without follow-up testing could be adopted for influenza-positive patients.
Open AccessRedesigning Isolation Practices: Evaluation of a Comprehensive Protocol for Respiratory Virus Control Including Cycle Threshold (Ct) Value Dynamics
The recent literature has debunked the widespread hypothesis that viruses are primarily transmitted via droplets and not beyond 1.5 m, and transmission via contact has been downplayed. Hence, an evidence-based revision of the existing isolation guidelines for respiratory viruses was needed. Therefore, a completely new protocol for respiratory virus isolation in terms of personal protective equipment and patient room air purification was evaluated. Isolation relief criteria based on Ct values in follow-up sampling were assessed. A Ct value of <28 was employed as a proxy for potential active replication and associated transmissibility. Between 25% and 50% of patients who tested positive for RSV, HRV, hMPV, or SARS-CoV-2 continued to exhibit high viral loads on day 7 post-initial diagnosis, underscoring the potential for sustained infectivity. Hence, the discontinuation of isolation measures for these patients without follow-up testing may carry a considerable risk of ongoing viral transmission. On the contrary, only 7% of patients positive for Flu and 14% for PIV had a follow-up sample on day 7 with a Ct value of less than 28. Ct values increased more rapidly in influenza, indicating faster viral clearance compared to other respiratory viruses. Based on these results, the policy of a standard 7-day isolation period without follow-up testing could be adopted for influenza-positive patients.
- 23 October 2025
- Published by Massachusetts Medical Society in NEJM AI
- Vol. 2 (11)
Response: To the Comment on AI-Assisted Spirometry Interpretation in Primary Care: A Randomized Controlled Trial
- 23 October 2025
- Published by Massachusetts Medical Society in NEJM AI
- Vol. 2 (11)
Response: To the Comment on AI-Assisted Spirometry Interpretation in Primary Care: A Randomized Controlled Trial
- 24 July 2025
- Published by Massachusetts Medical Society in NEJM AI
- Vol. 2 (8)
AI-Assisted Spirometry Interpretation in Primary Care: A Randomized Controlled Trial
- 24 July 2025
- Published by Massachusetts Medical Society in NEJM AI
- Vol. 2 (8)
AI-Assisted Spirometry Interpretation in Primary Care: A Randomized Controlled Trial
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA2993
Machine learning models for different outcomes to better understand individual treatment response on COPD exacerbations in the IMPACT study
Aim: We aimed to develop a machine learning model, trained for time to first COPD exacerbation, to estimate individual treatment response to fluticasone furoate (FF) in addition to umeclidinium/vilanterol (U/V) in the IMPACT trial (NCT02164513), and compared this with a previous model for exacerbation rate. Methods: Patients in the FF/U/V (n=3989) and U/V (n=2001) arms were split (70:30) in a train (n=4193) and independent test set (n=1797). Using baseline characteristics, a t-learner of two random survival forests (one for each arm) was trained to predict changes in survival probability in response to added FF. We previously used the same train and test set to predict changes in exacerbation rate (Verstraete, K. et al. Thorax 2023; 78:983-989). Results: The survival model (C-index FF/U/V 0.59, U/V 0.63) identified a responder subgroup in the test set: hazard ratio (HR) 0.72 (p=0.01) for the 33% predicted best responders (Q1) and non-significant HR for the other 66% of the cohort (Q2 and Q3). Previously, the rate model found rate ratio (RR) 0.60 (p<0.001) for its Q1 and non-significant RR in Q2 and Q3. Patients in Q1, Q2 and Q3 for rate and survival overlapped partially. Patients predicted to be in Q1 by both models (n=271) were older (p=0.006), had milder disease (higher FEV1, lower SGRQ scores (both p<0.001)) but presented with more previous moderate exacerbations and higher blood eosinophil counts (both p<0.001) compared to patients predicted to be Q3 (33% worst responders) by both models (n=259). Conclusion: Combining models for different outcomes may better identify absolute treatment response versus nonresponse on individual patient level.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA2993
Machine learning models for different outcomes to better understand individual treatment response on COPD exacerbations in the IMPACT study
Aim: We aimed to develop a machine learning model, trained for time to first COPD exacerbation, to estimate individual treatment response to fluticasone furoate (FF) in addition to umeclidinium/vilanterol (U/V) in the IMPACT trial (NCT02164513), and compared this with a previous model for exacerbation rate. Methods: Patients in the FF/U/V (n=3989) and U/V (n=2001) arms were split (70:30) in a train (n=4193) and independent test set (n=1797). Using baseline characteristics, a t-learner of two random survival forests (one for each arm) was trained to predict changes in survival probability in response to added FF. We previously used the same train and test set to predict changes in exacerbation rate (Verstraete, K. et al. Thorax 2023; 78:983-989). Results: The survival model (C-index FF/U/V 0.59, U/V 0.63) identified a responder subgroup in the test set: hazard ratio (HR) 0.72 (p=0.01) for the 33% predicted best responders (Q1) and non-significant HR for the other 66% of the cohort (Q2 and Q3). Previously, the rate model found rate ratio (RR) 0.60 (p<0.001) for its Q1 and non-significant RR in Q2 and Q3. Patients in Q1, Q2 and Q3 for rate and survival overlapped partially. Patients predicted to be in Q1 by both models (n=271) were older (p=0.006), had milder disease (higher FEV1, lower SGRQ scores (both p<0.001)) but presented with more previous moderate exacerbations and higher blood eosinophil counts (both p<0.001) compared to patients predicted to be Q3 (33% worst responders) by both models (n=259). Conclusion: Combining models for different outcomes may better identify absolute treatment response versus nonresponse on individual patient level.